Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SLATE 001

Next Previous
Drug Profile

SLATE 001

Alternative Names: GRT-C903; GRT-C903/GRT-R904; GRT-R904; SLATE; SLATE Version (v)1; SLATE-001; SLATE-KRAS

Latest Information Update: 22 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gritstone Oncology
  • Developer Gritstone bio; National Cancer Institute (USA)
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Non-small cell lung cancer
  • Phase I/II Pancreatic cancer; Solid tumours
  • Phase I Cancer

Most Recent Events

  • 19 Apr 2024 Phase-I clinical trials in Cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT06253520)
  • 19 Apr 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT06253520)
  • 01 Oct 2023 US FDA approves IND application for SLATE-001 for phase I SLATE-KRAS trial

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top